<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03975374</url>
  </required_header>
  <id_info>
    <org_study_id>Sutphin T</org_study_id>
    <nct_id>NCT03975374</nct_id>
  </id_info>
  <brief_title>To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension</brief_title>
  <official_title>Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutphin Drugs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutphin Drugs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare and describe efficacy and safety of Tobradex
      ophthalmic suspension versus generic Tobramycin/dexamethasone Suspension in treatment of
      Blepharoconjuctivitis through clinical parameters
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of signs and symptoms during treatment, with a record of individual scores for
      each parameter; Observation and statistical comparison of drug safety, by recording
      qualitative and quantitative parameters related to adverse effects occurring during
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In group one, patients will be instructed to instill 2 gtt of Tobradex ophthalmic solution for 10 days.
In group two, patients will be instructed to instill 2 gtt of Tobramycin/dexamethasone solution for 10 days .</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sign and symptoms composite score</measure>
    <time_frame>10 days</time_frame>
    <description>The change from baseline in the signs and symptoms score. Global sign and symptom score defined as the total score of lid margin redness (0-3), lid swelling (0-4), bulbar conjunctival redness (0-3), palpebral conjunctival redness (0-3), ocular discharge (0-3), itchy eyelids (0-4), and gritty eyes (0-4).
The change from baseline to Day 10 (Visit 3 at day 1, day 7 and day 10) in the ocular signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Blepharo Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Tobramycin/Dexamethasone opthamic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of randomized patients will be instructed to instill 2 gtt of Tobramycin/Dexamethasone opthamic solution every 6 hours for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobradex Opthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of randomized patients will be instructed to instill 2 gtt of Tobradex Opthalmic Solution every 6 hours for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin/dexamethasone opthalmic solution</intervention_name>
    <description>To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution</description>
    <arm_group_label>Tobramycin/Dexamethasone opthamic Solution</arm_group_label>
    <other_name>Tobradex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobradex Opthalmic Solution</intervention_name>
    <description>Tobradex Opthalmic Solution</description>
    <arm_group_label>Tobradex Opthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All potential subjects with symptomatic blepharitis examined to have blepharitis with
             healthy mental status, able to give consent, with/without co-existing medical
             conditions will be considered

        Exclusion Criteria:

          -  All subjects with history and/or probable history of allergic reaction to
             tobramycin/dexamethasone and all subjects who have mental disability and are unable to
             give direct consent will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajai Prakash</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutphin Drugs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajai Prakash</last_name>
    <phone>7183260310</phone>
    <email>ajaiprakashny@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jayesh R patel</last_name>
    <phone>5166414687</phone>
    <email>jaysheela@aol.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sutphin Drugs</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11435</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ajai Prakash, PhD</last_name>
      <phone>718-326-0310</phone>
      <email>ajaiprakashny@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jayesh Patel</last_name>
      <phone>5166414687</phone>
      <email>healingathome13@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sutphin Drugs</investigator_affiliation>
    <investigator_full_name>Dr. Ajai Prakash</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Tobramycin, Dexamethasone Drug Combination</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

